ClinicalTrials.gg
CompletedNCT03381586Updated Mar 24, 2025Results posted

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

A Phase 1 interventional study of ALT-803 in Healthy, sponsored by Altor BioScience. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • ALT-803
  • PK
03

In context

Lead sponsor

Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before Altor BioScience became part of ImmunityBio, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Written

    1. Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of subject care.
    2. Subjects must be willing and able to comply with the scheduled visits, study drug dosing schedule, procedures, laboratory tests, and other requirements of the study.
  2. Study Population

    1. (BMI) must be within the range of 18 to 28 kg/m2. Subjects must weigh between 50 and 100 kg (inclusive).
    2. Subjects must be in good health as determined by past medical history, complete physical examination, vital signs and laboratory tests at screening.
  3. Age and Reproductive Status

    1. Men and women, 18 - 65 years of age.
    2. Female participants of must adhere to using a medically accepted method of up to 28 days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) WOCBP must agree to use effective contraception during the study and for at least 1 month following the last dose of the study drug.
    3. WOCBP must have a negative serum pregnancy test \< 14 days prior to first dose of the study drug. Non-childbearing is defined as greater than one year or surgically sterilized.
    4. Male subjects must be willing to use barrier contraception (i.e. condoms and spermicide) from the day of dosing until at least 1 month following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Medical History and Concurrent Diseases

    1. A past medical history of 12 lead abnormalities
    2. Subjects with a history of interstitial lung disease and/or pneumonitis.
    3. -positive.
    4. Significant illness within 2 weeks prior to dosing.
    5. Positive serology or active infection.
    6. Known disease requiring active treatment. Subjects with a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 4 weeks or 5 half-lives of registration are excluded.
    7. Psychiatric illness/social situations that would limit compliance with study requirements.
    8. Previous , unless basal or squamous cell carcinoma of the skin or cervical carcinoma in situ with a complete remission achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
    9. Loss of ≥ 475 mL blood volume or blood donation transfusion of any blood product within 3 months prior to screening.
    10. Other illness or laboratory abnormality that in the opinion of the Investigator should exclude the subject from participating in this study.
  2. Prohibited Treatments and/or Restricted Therapies

    1. Use of any prescription drugs within 4 weeks (hormonal methods of are allowed) or less than 5 half-lives prior to dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within 2 weeks or less than 5 half-lives prior to dosing.
    2. Exposure to any drug or placebo within 3 months of first dose of study drug.
    3. Previous treatment or clinical trial participation with monoclonal antibody therapy.
    4. History of drug or alcohol abuse within 12 months prior to dosing, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline.
    5. Transfusion of blood or any blood product within 3 months prior to screening.
    6. History of using nicotine-containing products or smoking more than 5 cigarettes weekly for at least three months prior to the study through the final evaluation.
  3. Allergies and Adverse Drug Reaction

    1. History of severe reactions to other monoclonal antibodies.
    2. Known history of clinically significant drug allergy at Screening or Baseline
  4. Sex and Reproductive Status a. Women who are pregnant or nursing.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Group A

    1.0 mg/ml ALT-803

    Drug: ALT-803

  • Experimental
    Group B

    2.0 mg/ml ALT-803

    Drug: ALT-803

Interventions

  • Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.

06

What researchers measure

Primary outcomes

  1. PK Profile - Half-life (t½)

    The period of time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: Up to 192 hours

  2. PK Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)

    Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration.

    Time frame: Up to 192 hours

  3. PK Profile - Apparent (Extravascular) Clearance (CL/F)

    apparent (extravascular) clearance (CL/F)

    Time frame: Up to 192 hours

  4. PK Profile - Maximum Observed Concentration (Cmax)

    maximum observed concentration (Cmax)

    Time frame: Up to 192 hours

  5. PK Profile - Time of the Observed Maximum Concentration (Tmax)

    time of the observed maximum concentration (Tmax)

    Time frame: Up to 192 hours

  6. PK Profile - Area Under the Plasma Concentration Curve From Time 0 Through the Last Measurable Concentration (AUC0-t)

    area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t)

    Time frame: Up to 192 hours

  7. PK Profile - Area Under the Plasma Concentration Curve From Time 0 Extrapolated to Infinite Time (AUC0-inf)

    area under the plasma concentration curve from time 0 extrapolated to infinite time (AUC0-inf)

    Time frame: Up to 192 hours

Secondary outcomes

  1. Number of Adverse Events

    Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

    Time frame: Up to 66 days

07

Results

Posted Mar 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup AGroup B
Started1010
Completed77
Not completed33
Withdrew: Adverse event11
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPK Profile - Half-life (t½)

The period of time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
Up to 192 hours
Reported as:
Mean · Days
PK Profile - Half-life (t½)
DaysGroup AGroup B
Period 1 (10 μg/kg)1.07 ± 0.8130.55 ± 0.095
Period 2 (20 μg/kg)1.02 ± 0.7580.68 ± 0.236
PrimaryPK Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)

Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration.

Time frame:
Up to 192 hours
Reported as:
Mean · mL/kg
PK Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)
mL/kgGroup AGroup B
Period 1 - 10 μg/kg13900 ± 120005360 ± 2790
Period 2 - 20 μg/kg15500 ± 1300011800 ± 8170
PrimaryPK Profile - Apparent (Extravascular) Clearance (CL/F)

apparent (extravascular) clearance (CL/F)

Time frame:
Up to 192 hours
Reported as:
Mean · mL/day/kg
PK Profile - Apparent (Extravascular) Clearance (CL/F)
mL/day/kgGroup AGroup B
Period 1 - 10 µg/kg8650 ± 54506610 ± 2680
Period 2 - 20 µg/kg10500 ± 543011000 ± 4440
PrimaryPK Profile - Maximum Observed Concentration (Cmax)

maximum observed concentration (Cmax)

Time frame:
Up to 192 hours
Reported as:
Mean · pg/mL
PK Profile - Maximum Observed Concentration (Cmax)
pg/mLGroup AGroup B
Period 1 - 10 µg/kg1150 ± 9451080 ± 902
Period 2 - 20 µg/kg1900 ± 19301490 ± 921
PrimaryPK Profile - Time of the Observed Maximum Concentration (Tmax)

time of the observed maximum concentration (Tmax)

Time frame:
Up to 192 hours
Reported as:
Median · Days
PK Profile - Time of the Observed Maximum Concentration (Tmax)
DaysGroup AGroup B
Period 1 - 10 µg/kg0.167 (0.167 to 2.00)0.583 (0.167 to 2.00)
Period 2 - 20 µg/kg1.00 (0.170 to 1.00)0.170 (0.170 to 0.171)
PrimaryPK Profile - Area Under the Plasma Concentration Curve From Time 0 Through the Last Measurable Concentration (AUC0-t)

area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t)

Time frame:
Up to 192 hours
Reported as:
Mean · Day*pg/mL
PK Profile - Area Under the Plasma Concentration Curve From Time 0 Through the Last Measurable Concentration (AUC0-t)
Day*pg/mLGroup AGroup B
Period 1 - 10 µg/kg1390 ± 7271240 ± 706
Period 2 - 20 µg/kg2370 ± 14101940 ± 1040
PrimaryPK Profile - Area Under the Plasma Concentration Curve From Time 0 Extrapolated to Infinite Time (AUC0-inf)

area under the plasma concentration curve from time 0 extrapolated to infinite time (AUC0-inf)

Time frame:
Up to 192 hours
Reported as:
Mean · Day*pg/mL
PK Profile - Area Under the Plasma Concentration Curve From Time 0 Extrapolated to Infinite Time (AUC0-inf)
Day*pg/mLGroup AGroup B
Period 1 - 10 µg/kg1600 ± 8971740 ± 731
Period 2 - 20 µg/kg2420 ± 14002130 ± 1000
SecondaryNumber of Adverse Events

Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

Time frame:
Up to 66 days
Reported as:
Count of participants · Participants
Number of Adverse Events
ParticipantsGroup AGroup B
Number of Adverse Events1010

Adverse events

Collected over Up to 66 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A0/10 (0%)0/10 (0%)10/10 (100%)
Group B0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Showing 10 of 54
Most frequent other events
EventGroup AGroup B
ChillsGeneral disorders9/1010/10
Injection site reactionGeneral disorders10/1010/10
Feeling of body temperature changeGeneral disorders4/108/10
PyrexiaGeneral disorders8/107/10
Abdominal pain lowerGastrointestinal disorders7/107/10
HeadacheNervous system disorders6/107/10
MyalgiaMusculoskeletal and connective tissue disorders4/105/10
Back painMusculoskeletal and connective tissue disorders1/104/10
CoughRespiratory, thoracic and mediastinal disorders4/101/10
LymphadenopathyBlood and lymphatic system disorders3/103/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Median46 ± 11.342.5 ± 11.644 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female549
Male5611
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group AGroup BTotal
Hispanic or Latino91019
Not Hispanic or Latino101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group AGroup BTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White91019
More than one race000
Unknown or Not Reported000
Healthy Volunteers
Healthy Volunteers(Participants)Group AGroup BTotal
Count of participants101020
08

Study locations

1 site
  • Quotient Sciences
    Miami, Florida 33126, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2018, 2 months.

Results were first posted in Mar 2025, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Dec 22, 2017
StartActual
Dec 27, 2017
Primary completionActual
Mar 13, 2018
CompletionActual
Mar 13, 2018
Results first posted
Mar 24, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03381586
Lead sponsor
Altor BioScience
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Dec 27, 2017
Primary completion
Mar 13, 2018
Completion
Mar 13, 2018
Results posted
Mar 24, 2025
Last update
Mar 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion